Clinical Edge Journal Scan

Post-LT HCC recurrence unaffected by donor sex


 

Key clinical point: Donor sex did not affect post-liver transplantation (LT) recurrence of hepatocellular carcinoma (HCC) and need not be considered during donor selection or organ allocation.

Major finding: After propensity score matching, the female donor (F-D) and male donor (M-D) groups showed comparable 5-year overall recurrence rates (15% vs. 14%; P = .63) and graft recurrence rates (5% vs. 5%; P = .94). Donor sex was not identified as a significant risk factor for HCC recurrence by either univariate or multivariate analysis.

Study details: This study evaluated 1118 patients with HCC who underwent LT receiving a liver graft from the F-D (n = 446) or M-D (n = 672) groups.

Disclosures: The authors did not declare any funding source or conflicts of interest.

Source: Taura K et al. No impact of donor sex on the recurrence of hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Sci. 2022 (Mar 13). Doi: 10.1002/jhbp.1134

Recommended Reading

Clinical Edge Journal Scan Commentary: HCC April 2022
Federal Practitioner
Aspirin use may be protective against HCC in chronic hepatitis B
Federal Practitioner
On-treatment HCC risk is inversely related to baseline viral load in HBeAg-positive chronic hepatitis B
Federal Practitioner
Surveillance for HCC occurrence in NAFLD: Why concentrate our efforts?
Federal Practitioner
Adjuvant SBRT after marginal resection: A safe therapeutic option for MVI-positive HCC
Federal Practitioner
Preliminary results call for evaluating AtezoBev in unresectable HCC beyond the CP-A criteria
Federal Practitioner
Unresectable HCC: Suboptimal response to lenvatinib plus pembrolizumab beyond the first-line setting
Federal Practitioner
Tenofovir vs. entecavir: Better therapeutic in HBV-related HCC after radiofrequency ablation
Federal Practitioner
TACE is safe and effective in elderly patients with intermediate HCC
Federal Practitioner
TACE vs. LR: Better prognosis in HCC with bile duct tumor thrombus?
Federal Practitioner